X-body, Inc.

X-chem, Inc.

Glaxosmithkline LLC

Phylos, Inc.

Compound Therapeutics, Inc.

Bristol-myers Squibb Compnay

Praecis Pharmaceuticals, Inc.

Adnexus Therapeutics, Inc.

Peter Lohse

Markus Kurz

Adnexus, a Bristol-myers Squibb R&d Company

Richard Wagner

Wagner, Richard W.

Richard W Wagner

Yan Chen

Matthew Clark

Malcolm L Gefter

Barry A Morgan

Dennis R Benjamin

David I Israel

Christopher C Arico-Muendel

Malcolm J Kavarana

Stephen Paul Hale

Nils Jakob Vest Hansen

Raksha A Acharya

Paolo A Centrella

George J Franklin

Alexander Litovchick

Robert G Kuimelis

Steffen Phillip Creaser

Dasa Lipovsek

Tod M Woolf

Anthony Dominic Keefe

Csaba Pazmany

Ying Victor Zhang

John William Cuozzo

Diana Gikunju

Heather Thomson

Steffan Phillip Creaser

Keming Zhang

Pascale Richalet

Nils Jakob Hansen

Martin C Wright

Brent L Kreider

Christopher D Hupp

Paulo A Centrella

Ying Zhang

Anthony D Keefe

John W Cuozzo

Mathew A Clark

John Cuozzo

Brent Kreider

The present invention provides antigen-binding polypeptides, including bi-specific antigen-binding polypeptides, that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease, including cancer, are also encompassed by the invention.

Bi-specific antigen-binding polypeptides

Provided are methods and compositions for the production of novel antibodies that bind specifically to a target antigen. These methods and compositions are particularly useful for producing antibodies having the antigen binding specificity of a reference antibody but with improved properties (e.g., binding affinity, immunogenicity, and thermodynamic stability) relative to the reference antibody.

Antibody screening methods

The invention provides methods and compositions useful for identifying polypeptides with desired characteristics in vitro.

X-display complexes for protein screening methods

The present invention features a number of methods for identifying one or more compounds that bind to a biological target. The methods include synthesizing a library of compounds, wherein the compounds contain a functional moiety having one or more diversity positions. The functional moiety of the compounds is operatively linked to an initiator oligonucleotide that identifies the structure of the functional moiety.

Methods of creating and screening DNA-encoded libraries

The present invention provides binding polypeptides (e.g., antibodies or fragments thereof) that specifically bind to a target antigen (e.g., a human antigen, e.g., human PDGFR&#x3b2;) with high affinity. The invention also provides, libraries of binding polypeptides, pharmaceutical compositions, as well as nucleic acids encoding binding polypeptides, recombinant expression vectors and host cells for making such binding polypeptides. Methods of using binding polypeptide of the invention to diagnose and treat disease are also encompassed by the invention.

PDGF receptor beta binding polypeptides

The present invention relates to oligonucleotide-encoded libraries and methods of tagging such libraries. In particular, the methods and oligonucleotides can include one or more 2'-substituted nucleotides, such as 2&#x2032;-O-methyl or 2&#x2032;-fluoro nucleotides, and other conditions or reagents to enhance enzyme ligation or one or more chemical functionalities to support chemical ligation.

Methods for tagging DNA-encoded libraries

Protein screening methods

The present invention provides antigen-binding polypeptides (e.g., bi-specific antigen-binding polypeptides) that specifically bind to a first and a second target antigen with high affinity. The present invention also provides novel antigen-binding polypeptides that specifically bind to HER2 and antagonize HER2 activation. The invention also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen binding polypeptides. Methods of using antigen-binding polypeptide of the invention to treat disease (e.g., cancer) are also encompassed by the invention.

Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.

Protein scaffolds for antibody mimics and other binding proteins

The present invention features benzhydrol-pyrazole derivatives and related compounds having kinase inhibitory activity. The compounds of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions, such as cancers, inflammatory disorders, or autoimmune disorders.

Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof

Growing community of inventors

Cambridge, MA, United States of America

Richard W Wagner